Clinical trials: Primary Immune Thrombocytopenia
Herombopag
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
The objective of this study was to evaluate the efficacy and safety of Herombopag in the treatment of elderly patients with ITP.
- Trial name
- NCT06838949
- Testing
- herombopag olamine tablets
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenia (ITP)
Study of Immune Thrombocytopenia Pathogenesis:
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells.
- Trial name
- PTI PARI (NCT02042560)
- Testing
- Blood samples, Spleen samples
- Where
- 3 sites in France
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Immune Thrombocytopenia
Risk Factors for Thrombosis in Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is a rare autoimmune disease (annual incidence: 3-4/105 inhabitants) leading to an increased risk of spontaneous bleeding.
- Trial name
- RiFT-ITP (NCT03820960)
- Where
- France
- Volunteers
- 10,039 people
- Sponsor
- University Hospital, Toulouse
Primary Immune Thrombocytopenia
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP…
- Trial name
- NCT06900920
- Testing
- TQB3473 Tablets
- Where
- 53 sites in China
- Volunteers
- 199 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Immune Thrombocytopenia
Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of glycyrrhetinic acid combining with high-dose dexamethasone for the treatment of adults with…
- Trial name
- NCT03998982
- Testing
- Glycyrrhetinic Acid, Dexamethasone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong University
Immune Thrombocytopenia
End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia
This study proposes to observe whether a stable platelet count would be maintained without additional treatment in the long term in at least a proportion of patients who have discontinued eltrombopag taken for at least 4 months.
- Trial name
- NCT01386723
- Testing
- Discontinuation of eltrombopag
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Weill Medical College of Cornell University
Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use
Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma
This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma
- Conditions
- Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use, Lymphoma
- Trial name
- NCT04797182
- Testing
- avatrombopag
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Primary Thrombocytopenia
Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia
NewGam is a newly developed human normal immunoglobulin solution for intravenous administration (IGIV). This study will evaluate the safety and efficacy of NewGam 10% in patients with primary immune thrombocytopenia.
- Trial name
- NCT01349790
- Testing
- NewGam
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Octapharma
Persistent or Chronic ITP
Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP
Thrombopoietin-receptor agonists (Tpo-RAs) have profoundly changed the management of ITP. However, today, there are no international recommendations concerning the long-term use of these costly, potentially pro-thrombotic agents…
- Trial name
- STOP-AGO (NCT03119974)
- Testing
- Tpo-RA discontinuation
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenia (ITP)
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly…
- Trial name
- NCT07065968
- Testing
- Teriflunomide, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia
Herombopag + rhTPO in Severe Immune Thrombocytopenia
Severe immune thrombocytopenia (ITP) is a life-threatening acquired hemorrhagic disease with dramatically decreased platelet number and clinical bleeding symptoms.
- Trial name
- NCT05328804
- Testing
- rhTPO, Herombopag
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Yin Jie
Thrombocytopenia
The International ITP Registry
Primary immune thrombocytopenia (ITP) is an uncommon disease characterised by a low platelet count, which may cause the patient to have a higher risk or increased duration of bleeding.
- Trial name
- NCT01970189
- Where
- 44 sites in Australia, Colombia and 8 more
- Volunteers
- 500 people
- Sponsor
- South Eastern Sydney Local Health District
Refractory Systemic Lupus Erythematosus, Lupus Nephritis
CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus
Investigator-initiated, single-arm, open-label, single dose clinical study to evaluate the safety and preliminary efficacy of CNCT19 in treatment of patients with refractory systemic lupus erythematosus(SLE) presented with active…
- Conditions
- Refractory Systemic Lupus Erythematosus, Lupus Nephritis, Immune Thrombocytopenia
- Trial name
- NCT05930314
- Testing
- CNCT19 cell injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking Union Medical College Hospital
Immune Thrombocytopenia, ITP
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge…
- Trial name
- ADOPT (NCT04943042)
- Testing
- Avatrombopag
- Where
- 55 sites in Croatia, Czechia and 7 more
- Volunteers
- 199 people
- Sponsor
- Swedish Orphan Biovitrum
Primary Immune Thrombocytopenia
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.
- Trial name
- ADVANCE (NCT04188379)
- Testing
- efgartigimod
- Where
- 121 sites in United States, Austria and 16 more
- Volunteers
- 131 people
- Sponsor
- argenx
Immune Thrombocytopenia, Pregnancy
Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy
This clinical trial is undertaking by Qilu Hospital of Shandong University, aims at evaluating efficacy and safety of rhTPO in management of ITP in pregnancy.
- Trial name
- NCT02270801
- Testing
- rhTPO
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong University
Immune Thrombocytopenia
An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
The project was undertaking by Qilu Hospital of Shandong University and other 7 well-known hospitals in China. In order to report the efficacy and safety of different dose dexamethasone in treating the immune thrombocytopenia…
- Trial name
- NCT02153060
- Testing
- Dexamethasone
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shandong University
Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
The goal of this observational study is to characterize the diagnostic and therapeutic management of autoimmune cytopenias including autoimmune hemolytic anemia, immune thrombocytopenia, and chronic idiopathic/autoimmune…
- Conditions
- Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia, Autoimmune Neutropenia
- Trial name
- AIHA ITP CIN (NCT05931718)
- Testing
- cytokine essays, NGS, Fecal microbiome
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
ITP, Immune Thrombocytopenia
The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of iguratimod and danazol versus danazol for the treatment of adults with steroid-resistant/ relapse immune thrombocytopenia (ITP).
- Trial name
- NCT05281068
- Testing
- Iguratimod, Danazol
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of LIV-GAMMA SN Inj.10% administered for 2 days in adult subjects with primary immune thrombocytopenia (ITP).
- Trial name
- NCT05566990
- Testing
- LIV-GAMMA SN Inj.10%
- Where
- 11 sites in South Korea
- Volunteers
- 34 people
- Sponsor
- SK Plasma Co., Ltd.